Compare Eli Lilly And Co (LLY) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs STMicroelectronics NV — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while STMicroelectronics NV trades at $51.95 (market cap $48.14B). The key difference: Eli Lilly And Co is far larger — about 21.6× STMicroelectronics NV's market cap, and STMicroelectronics NV pays the higher dividend (0.68%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and STMicroelectronics NV for 64 Days on average.
| LLY | STM | |
|---|---|---|
Market Cap | $1.04T | $48.14B |
Volume | 3,064,878 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $1.28K | $79.91 |
52-Week Low | $799.57 | $21.20 |
Typical Hold Time | 93 Days | 64 Days |
Enterprise Value | $1.09T | $45.66B |
Dividend Yield | 0.59% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
STM (STMicroelectronics) trades at $51.88, down 7.65% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 101.49 and negative net income margin of -0.39%, though Q2 2026 EPS beat expectations. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2 billion by 2027. Cash flow improved in 2025 with net cash flow of $555 million, while the balance sheet remains solid with total assets of $24.74 billion.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings (51.72%) and a $77.31 price target, implying significant upside. Key risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Near-term performance hinges on execution of AI and automotive growth initiatives, with Q3 2026 earnings as a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
